Walgreens Boots (NASDAQ) reported FQ2 in excess of the consensus estimate of $1.37/share.

The period saw sales of $33.76 Billion, which was also higher than the consensus estimate of $33.32B. U.S. sales reached $27.67 trillion, close to what was expected at $27.71 billion. Global sales reached $5.56 trillion, lower than analyst estimates of $5.68billion.

An adjusted gross margin was 22.8% for the pharmaceutical company, which is higher than analyst expectations at 22%. According to Walgreens, 11.8 Million vaccines were administered in the second quarter.

The company stated that 102 of its co-located clinics were now open. It plans to have more than 200 in the CY22 year end. Additionally, it expects to completely reopen U.S. assistance offices in April 4.

For the entire fiscal year, the company anticipates a low single-digit adjustment in EPS growth.

Rosalind Brewer (CEO) stated that the strategic review of Boots is moving along and that transformational measures are driving sustainable value creation.

Walgreens Health’s second quarter revenue was $527 million. This is due to the purchase of VillageMD. Pro forma, these businesses saw a total growth rate of 128% in quarter compared to the year before.

Eric Coldwell, Baird Analyst, isn’t shocked by the retained guidance.

As COVID becomes more prevalent in the next quarters, we need to know where the EPS base should be. In a note to clients, an analyst said that Tone was positive and Walgreens has made progress, but that the mid-term remains elusive.

Elizabeth Anderson, Evercore ISI Analyst said the unchanged outlook implies a lower back half consensus than the Street consensus. However she did note that Q2 was very strong overall.

WBA shares are down by 6% today

By Senad Karaahmetovic